Novel truncating variants in FGD1 detected in two Danish families with Aarskog–Scott syndrome and myopathic features

Allan Bayat1,2 | Bjørg Krett3 | Morten Dunø4 | Pernille Mathiesen Torring5 | John Vissing3

Abstract
Aarskog–Scott syndrome (AAS) is a developmental disorder, caused by disease-causing hemizygous variants in the FGD1 gene. AAS is characterized by dysmorphic features, genital malformation, skeletal anomalies, and in some cases, intellectual disability and behavioral difficulties. Myopathy has only been reported once in two affected siblings diagnosed with AAS. Only few adult cases have been reported. This article reports four adults with AAS (three male cases and one female carrier) from two unrelated Danish families, all males presented with variable features suggestive of myopathy. All four carried novel hemizygous pathogenic variants in the FGD1 gene; one family presented with the c.2266dup, p.Cys756Leufs*19 variant while the c.527dup; p.Leu177Thrfs*40 variant was detected in the second family. All males had some mild myopathic symptoms or histological abnormalities. Case 1 had the most severe myopathic phenotype with prominent proximal muscular fatigue and exercise intolerance. In addition, he had multiple deletions of mtDNA and low respiratory chain activity. His younger nephew, case 3, had difficulties doing sports in his youth and had a mildly abnormal muscle biopsy and relatively decreased mitochondrial enzyme activity. The singular case from family 2 (case 4), had a mildly myopathic muscle biopsy, but no overt myopathic symptoms. Our findings suggest that myopathic involvement should be considered in AAS.

KEYWORDS
Aarskog–Scott syndrome, adulthood, developmental disorder, FGD1, mitochondrial myopathy

1 | INTRODUCTION
Aarskog–Scott syndrome (AAS) is inherited by an X-linked trait (OMIM#305400) and is caused by hemizygous disease-causing variants in the FYVE, RhoGEF, and PH domain containing 1 (FGD1) gene (OMIM#300546) (Orrico et al., 2004). AAS is characterized by short stature, dysmorphic features, genital malformation, and skeletal anomalies. In some cases, intellectual disability and behavioral difficulties have been reported (Orrico et al., 2004; Pasteris et al., 1994; Teebi et al., 1993; Zanetti Drumond et al., 2021). Female carriers have

Abbreviations: AAS, Aarskog-Scott syndrome; COX, cytochrome c oxidase; EMG, electromyography; ENG, electrical neurography; FGD1, faciogenital dysplasia protein; MRI, magnetic resonance imaging; MRC, Medical Research Council; mtDNA, mitochondrial DNA; PCR, polymerase chain reaction; SCR, succinate cytochrome c reductase; SDH, succinate dehydrogenase.

Allan Bayat and Bjørg Krett contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals LLC.

Am J Med Genet. 2022;188A:2251–2257.

wileyonlinelibrary.com/journal/ajmga
milder features (Orrico et al., 2010; Teebi et al., 1993). Clinical features are easily confused with those of a number of other complex syndromes including Noonan syndrome and Robinow syndrome (Bae et al., 2020; Ge et al., 2017). Genetic testing should be performed in order to reach a definite diagnosis of AAS.

According to the Leiden Open Variation Database, 54 AAS cases with a genetic diagnosis have been reported (https://databases.lovd.nl/shared/genes/FDG1). Therefore, our knowledge about the phenotypic spectrum in AAS remains limited. Myopathic symptoms have only been described once (Al-Semari et al., 2013).

In this case series, we describe three adult AAS cases, with varying severity of disease, and one female carrier from two unrelated Danish families. We describe myopathic features and mitochondrial changes, which may be an additional phenotypic feature of AAS.

2 | METHODS

All cases were seen at our clinic and underwent clinical examinations. Clinical records were reviewed for congenital anomalies, developmental history, and signs of myopathy. Further medical information was collected by interviewing families.

All cases underwent muscle biopsy. We performed PCR of mitochondrial DNA (mtDNA) on biopsies and assessed them for mitochondrial complex I-IV and citrate synthase activities. Muscle biopsies were histologically examined and stained for cytochrome c oxidase (COX), succinate dehydrogenase (SDH), combined COX/SDH, hematoxylin and eosin (H&E), Gomori trichrome, Oil Red, Myosin heavy chain-slow and-fast.

Peripheral blood DNA was used for sequence analysis of the coding regions of the FGD1 gene using standard Sanger sequencing according to routine diagnostic protocols. NM_004463.3 was used as reference sequence. Peripheral blood DNA from proband in family 1 was subsequently exom-sequenced to assess for potential additional genetic predispositions.

3 | CASE PRESENTATION

We identified four adults with pathogenic variants in the FGD1 gene. Three male cases and one female carrier. The cases belonged to two unrelated Danish families with Aarskog–Scott syndrome. Figure S1, Supporting Information shows the pedigrees of the two affected families.

3.1 | Case 1: Proband, family 1

The proband of family 1, a 57-year-old man, was referred to our hospital due to muscular complaints. Two years before, he developed constant pain from muscles and joints, especially affecting proximal muscles in the lower extremities and hip and knee joints bilaterally. Symptoms were not responsive to mild analgesic drugs such as paracetamol and ibuprofen and were triggered by everyday physical activity but were also noticeable at rest. He had left-sided tinnitus and intermittent left-sided headache. There was no history of seizures, stroke, or stroke-like episodes. He was on no medication. At birth he was diagnosed with bilateral ptosis. Orchiopexy for bilateral cryptorchidism was performed when he was 2 years old. His intellectual performance at school was reduced due to a learning disability including challenges with reading and writing. No data were available on developmental milestones nor on any formal cognitive assessments carried out during childhood. He attended a special needs class, finished primary school, and never received a formal education; subsequently, he has been employed as an unskilled worker.

On physical exam, his height was 167 cm (–2.2 SD) and his weight was 74 kg (0 SD). He had a broad nasal bridge, widely spaced eyes, prominent forehead, and a wide philtrum (Figure 2a–c). His hands were small and broad with brachydactyly and interdigital webbing (Figure 2d). Hyperextension of the proximal interphalangeal joint and flexion of the distal interphalangeal joint were observed. He had ulnar neuropathy on the left hand, following a complex arm fracture. Medical Research Council (MRC) muscle strength assessment was normal. There was no shawl scrotum. Ophthalmologic evaluation revealed external ophthalmoplegia and ptosis but no sign of pigmentary retinopathy, nystagmus, or renal vessel tortuosity. Magnetic resonance imaging (MRI) of the central nervous system was normal. MRI of lower extremities did not show fat replacement of muscles, atrophy, or edema. Electroneurography and electromyography, echocardiography, and creatine kinase levels were normal.

A novel hemizygous, likely pathogenic, truncating variant was detected in exon 15 of the FGD1 gene (c.2266dup, p.Cys756Leufs*19, NM_004463.3). He also carried a rare heterozygous frameshift variant in the patatin-like phospholipase domain-containing protein 2 gene (PNPLA2); (NM_020376.4) c.798del, p.(Ala267Profs*53). This variant is not reported in ClinVar (Landrum & Kattman, 2018) and has an allele frequency of 0.00008692 (2/230108) in The Genome Aggregation Database (Karczewski et al., 2020). Biallelic pathogenic variants in PNPLA2 are associated with neutral lipid storage disease (NLSD), an autosomal recessive disorder characterized by severe accumulation of triglyceride cytoplasmic droplets in several tissues including muscles (Janssen et al., 2013). Muscle biopsy showed multiple COX-negative fibers and weakly stained fibers in SDH, indicating relative mitochondrial depletion (Figure 2a,b). No triglyceride droplets were seen in oil red stain. He was also found to have multiple mtDNA deletions at a higher load than expected for age (mtDNA from muscle tissue). In accordance with the apparent mitochondrial depletion on COX and SDH stains, mitochondrial complex activities for complexes I and IV were also decreased when compared to the citrate synthase activity (Table 1).

3.2 | Case 2: Family 1

A 74-year-old woman, sister to case 1 and mother to case 3, was a carrier of the familial FGD1 variant. She had no comorbidities. Fifteen
years earlier, she experienced symptoms indicative of acute inflammatory demyelinating polyradiculitis, but had full remission in the year after.

Clinical examination showed a widow’s peak and downslanting palpebral fissures (Figure 2e–g). She had no other dysmorphic signs of AAS. Neurologic examination, muscle strength, muscle biopsy findings and mitochondrial complex and citrate synthase activities were all normal. She also carried the c.2266dup, p.Cys756Leufs*19 variant.

3.3 | Case 3: Family 1

A 38-year-old man was nephew to the proband and the son of case 2. He was unemployed but had done physically strenuous work most of his life. He previously underwent surgery for a cleft lip and palate and for maldescent of testis. Despite not having a growth hormone deficiency, he was treated with such until 13 years of age due to his short stature. The treatment was stopped as it did not improve the growth velocity. He experienced a mild learning disability with spelling difficulties in school. He found it difficult to participate in physical activities during his youth. He is currently on no medication.

On physical exam, height was 1.62 cm (±3.0 SD), weight 59.7 kg (±1.7 SD) and he presented with widely spaced eyes, mild ptosis, downslant palpebral fissures, low set ears, short philtrum, high palate, and mild dysarthria (Figure 1i–k). Extremities showed brachydactyly and interdigital webbing. No scrotal shawl or inguinal hernia. Muscle bulk, MRC strength assessment, and general neurologic exam were normal. He also carried the c.2266dup, p.Cys756Leufs*19 variant. Muscle biopsy showed central nuclei and few COX-negative fibers (Figure 2c,d). Mitochondrial enzyme activities corrected for citrate synthase activity were moderately decreased for complexes I and IV (Table 1). There were no mtDNA deletions.

3.4 | Case 4: Family 2, proband

Case 4 was a 47-year-old man unrelated to family 1. He receives no medication and works at a protected institution, due to mild intellectual disability. He reported no issues doing physical activities and regularly runs 25–30 km. He underwent operation for maldescent of testes and multiple operations for inguinal hernia bilaterally.

On physical exam, his height was 159 cm (±3.4 SD) and he weighed 64 kg (±1.1 SD). Through childhood he had very short stature, and at 9 years of age his height was 4 SDs below normal. His features are characteristic of Aarskog-Scott syndrome with widely spaced eyes, flat nasal bridge, low set ears, broad hands and feet, single transverse palmar crease, and sandal gap bilaterally. He has a mild shawl scrotum and has been myopic since childhood (±5.5/±5.5) but otherwise with normal ophthalmological evaluation.

A truncating likely pathogenic variant was detected in FGD1 (c.527dup, p.Leu177Thrfs*40). His muscle biopsy showed a higher prevalence of type 1 fibers and few COX-negative fibers (Figure 2e). Mitochondrial enzyme complexes and citrate synthase activities were normal.

4 | DISCUSSION

We present three adult men with AAS and a female carrier from two unrelated families, affected by two novel likely pathogenic FGD1 variants and describe mitochondrial anomalies and myopathic features in the cases. All cases showed classic presentations of AAS with dysmorphic features and short stature.

Previous reports on cases with AAS have shown the majority of FGD1 variants to be unique within families; no variant hotspots or common variants have yet been recorded for this disease (Orrico et al., 2004). Lists of disease-causing variants of the FGD1 gene can be found at Leiden Open Variation Database (https://databases.lovd.nl/shared/genes/FGD1) and Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff (http://www.hgmd.cf.ac.uk/ac/index.php). According to ClinVar, 156 pathogenic and 14 likely pathogenic variants affecting the FGD1 gene have been characterized (Landrum & Kattman, 2018). These comprise nine missense variants, 10 frameshift variants, 10 nonsense variants, four splice site variants, one in-frame deletion and 75 large-scale deletions. No definite genotype-phenotype correlation is apparent from comparison of cases with different variants (Orrico et al., 2004; Orrico et al., 2015).

The FGD1 gene encodes the FGD1 protein, a guanine nucleotide exchange factor that activates the Rho GTPase Cdc42 (3,10) and may also affect growth control and nuclear signaling (Whitehead et al., 1998). FGD1 and CDC42 together, influence cell growth, cell cycle progression and transcription (Whitehead et al., 1998). Hence, a deficient FGD1 with such extensive cellular functions may

### TABLE 1 Mitochondrial complex I-IV and citrate synthase (CS) activities

| Reference | Case 1 | Case 2 | Case 3 | Case 4 | Unit |
|-----------|--------|--------|--------|--------|------|
| I/CS      | 0.19–0.54 | 0.14* | 0.31 | 0.13* | 0.39 | mU/mU |
| II/CS     | 0.24–0.5 | 0.23* | 0.38 | 0.26 | 0.38 | mU/mU |
| SCR/CS    | 0.19–0.72 | 0.21 | 0.39 | 0.23 | 0.37 | mU/mU |
| III/CS    | 0.72–2.14 | 0.67* | 1.32 | 1.08 | 1.7 | mU/mU |
| IV/CS     | 2.2–5 | 2.2 | 4.3 | 2.1* | 3.6 | mU/mU |

Note: Asterisk (*) denotes results outside reference values. Abbreviation: SCR, succinate cytochrome c reductase.
theoretically cause oxidative stress, which has been shown to cause secondary mitochondrial dysfunction or destabilization of other cellular functions leading to mitochondrial dysfunction (Schwartz et al., 2000).

Among our AAS cases, all cases had some mild myopathic symptoms or histological abnormalities. Thus, case 1 had the most severe myopathic phenotype with prominent muscular fatigue and exercise intolerance. In addition, he had multiple deletions in mtDNA and low respiratory chain activity. His younger nephew, case 3, had difficulties doing sports in his youth and had a mildly abnormal muscle biopsy and relatively decreased mitochondrial enzyme activity. The singular case from family 2 (case 4), had a possibly myopathic muscle biopsy, but no overt myopathic symptoms. Hence, the AAS cases seen at our center displayed varying degrees of myopathic pathology.

Biallelic variants in PNPLA2 lead to NLSD while carriers commonly have no organ involvement; a few carriers have been reported to have
muscle weakness, episodes of muscle pain and significant neutral lipid storage in muscle (Janssen et al., 2013). Case 1 was a carrier but had no lipid accumulation in his muscle biopsy. Although we cannot rule out that the heterozygous PNPLA2 could contribute to his phenotype, this variant is less likely to explain the mitochondrial dysfunction.

Myopathic laboratory findings have previously been reported in one AAS family published in 2013 with a nonsense variant in exon 6 (Al-Semari et al., 2013). In that report, two children had muscle biopsies showing increased subsarcolemmal staining of mitochondria and the authors argued that while the findings were not diagnostic, they were suggestive of a mitochondrial myopathy. They did not find any respiratory chain defects and did not report any myopathic symptoms.

Myopathic symptoms in AAS may be somewhat age dependent. Many AAS cases have ptosis, but few report other signs of myopathy. The prominent myopathic symptoms of case 1, started at age 55 years. The other two male AAS cases, aged 38 and 47, have somewhat abnormal histology and mitochondrial enzyme activity, but they did not report significant myopathic symptoms. Previously published reports of AAS have mainly included children and very few adults older than 30 years (Al-Semari et al., 2013; Altinçık et al., 2013; Aten et al., 2013; Bedoyan et al., 2009; Bottani et al., 2007; Lebel et al., 2002; Orrico et al., 2004; Orrico et al., 2007; Pilozzi-Edmonds et al., 2011; Ronce et al., 2012; Schwartz et al., 2000; Verhoeven et al., 2012). Myopathic symptoms, which emerge in older AAS cases, may be caused by a secondary mitochondrial dysfunction, because of increased cumulative mtDNA damage. This may possibly explain the lack of reported myopathy among AAS cases, as reported cases have been relatively young and not yet cumulated sufficient mtDNA damage to reach a symptomatic threshold. It is also likely that since few cases undergo muscle biopsy, cases of asymptomatic myopathic histology in younger AAS cases, may not have been recognized. Lastly, myopathic symptoms may be unspecific and easily overlooked in older cases. There is already one previously published AAS family with reported myopathy and we found myopathic pathology in two unrelated families. Therefore, it is possible that the reported mitochondrial pathology is associated with AAS.

5 | CONCLUSION
Based on our findings, we suggest that mitochondrial dysfunction could be responsible for some of the symptoms in AAS. None of our cases fulfill the criteria for a definite diagnosis of a respiratory chain disorder (Bernier et al., 2002). However, we report unspecific mitochondrial and myopathic symptoms that are backed by histological, enzymological and molecular pathologic findings, which seem to suggest that myopathy and mitochondrial dysfunction may be considered in AAS, especially in older cases.
CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

AUTHOR CONTRIBUTIONS
John Vissing and Allan Bayat contributed to the initialization of the study. John Vissing, Pernille Mathiesen Torring, Morten Dunø, and Allan Bayat performed clinical examination and laboratory investigations. The article was drafted by Bjørg Krett. All authors have approved the final article.

DATA AVAILABILITY STATEMENT
Data concerning the published participants are available upon request.

ORCID
Allan Bayat https://orcid.org/0000-0002-3522-9767

REFERENCES
Al-Semari, A., Wakil, S. M., Al-Muhaizea, M. A., Dababo, M., Al-Amr, R., Alkuraya, F., & Meyer, B. F. (2013). Novel FGD1 mutation underlying Aarskog–Scott syndrome with myopathy and distal arthropathy. Clinical Dysmorphology, 22(1), 13–17. https://doi.org/10.1097/MCD.0b013e32835b6dc4
Altincik, A., Kaname, T., Demir, K., & Bober, E. (2013). A novel mutation in a mother and a son with Aarskog–Scott syndrome. Journal of Pediatric Endocrinology & Metabolism, 26(3–4), 385–388. https://doi.org/10.1515/jpem-2012-0233
Aten, E., Sun, Y., Almomani, R., Santen, G. W., Messemaker, T., Maas, S. M., Breuning, M. H., & den Dunnen, J. T. (2013). Exome sequencing identifies a branch point variant in Aarskog–Scott syndrome. Human Mutation, 34(3), 430–434. https://doi.org/10.1002/humu.22252
Bae, G. Y., Kim, M. S., Kim, J. Y., Jang, J. H., Lee, S. M., Cho, S. Y., & Jin, D. K. (2020). The first Korean family with Aarskog–Scott syndrome harboring a novel mutation in FGD1 diagnosed via targeted gene panel sequencing. Annals of Clinical and Laboratory Science, 50(5), 691–698.
Bedoyan, J. K., Friez, M. J., DuPont, B., & Ahmad, A. (2009). First case of deletion of the faciogenital dysplasia 1 (FGD1) gene in a patient with Aarskog–Scott syndrome. European Journal of Medical Genetics, 52(4), 262–264. https://doi.org/10.1016/j.ejmg.2008.12.001
Bernier, F. P., Boneh, A., Dennett, X., Chow, C. W., Cleary, M. A., & Thorburn, D. R. (2002). Diagnostic criteria for respiratory chain disorders in adults and children. Neurology, 59(9), 1406–1411. https://doi.org/10.1212/01.wnl.0000033795.17156.00
Bottani, A., Orrico, A., Galli, L., Karam, O., Haenggeli, C. A., Ferrey, S., & Conrad, B. (2007). Unilateral focal polymicrogyria in a patient with classical Aarskog–Scott syndrome due to a novel missense mutation in an evolutionarily conserved RhoGEF domain of the faciogenital dysplasia gene FGD1. American Journal of Medical Genetics. Part A, 143A(19), 2334–2338. https://doi.org/10.1002/ajmg.a.31733
Ge, Y., Li, N., Wang, Z., Wang, J., & Cai, H. (2017). Novel variant in the FGD1 gene causing Aarskog–Scott syndrome. Experimental and Therapeutic Medicine, 13(6), 2623–2628. https://doi.org/10.3892/etm.2017.4301
Janssen, M. C., van Engelen, B., Kapusta, L., Lammens, M., van Dijk, M., Fischer, J., Graaf, M. V. D., Wevers, R. A., Fahrleitner, M., Zimmermann, R., & Morava, E. (2013). Symptomatic lipid storage in carriers for the PNPLA2 gene. European Journal of Human Genetics, 21(8), 807–815. https://doi.org/10.1038/ejhg.2012.256
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alfoldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., Gauthier, L. D., Brand, H., Solomonson, M., Watts, N. A., Rhodes, D., Singer-Berk, M., England, E. M., Seaby, E. G., Kosmicki, J. A., … Mac-Arthur, D. G. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 581(7809), 434–443. https://doi.org/10.1038/s41586-020-2308-7
Landrum, M. J., & Kattman, B. L. (2018). ClinVar at five years: Delivering on the promise. Human Mutation, 39(11), 1623–1630. https://doi.org/10.1002/humu.23641
Lebel, R. R., May, M., Poulis, S., Lubs, H. A., Stevenson, R. E., & Schwartz, C. E. (2002). Non-syndromic X-linked mental retardation associated with a missense mutation (P312L) in the FGD1 gene. Clinical Genetics, 61(2), 139–145. https://doi.org/10.1034/j.1399-0004.2002.610209.x
Orrico, A., Galli, L., Cavaliere, M. L., Gravelli, L., Fryns, J. P., Crushell, E., Rinaldi, M. M., Meidea A., & Sorrentino, V. (2004). Phenotypic and molecular characterisation of the Aarskog–Scott syndrome: A survey of the clinical variability in light of FGD1 mutation analysis in 46 patients. European Journal of Human Genetics, 12(1), 16–23. https://doi.org/10.1038/sj.ejhg.5201081
Orrico, A., Galli, L., Clayton-Smith, J., & Fryns, J. P. (2015). Clinical utility gene card for: Aarskog–Scott syndrome (faciogenital dysplasia)–Update 2015. European Journal of Human Genetics, 23, 4. https://doi.org/10.1038/ejhg.2014.178
Orrico, A., Galli, L., Faivre, L., Clayton-Smith, J., Azzarelli-Burri, S. M., Hertz, S., Jacquemont, S., Taurisano, R., Arroyo Carrera, I., Tarantini, E., Devriendt, K., Melis, D., Thelle, T., Meinhartd, U., Sorrentino, V. (2010). Aarskog–Scott syndrome: Clinical update and report of nine novel mutations of the FGD1 gene. American Journal of Medical Genetics. Part A, 152(2), 313–318. https://doi.org/10.1002/ajmg.a.33199
Orrico, A., Galli, L., Obregon, M. G., de Castro Perez, M. F., Falciani, M., & Sorrentino, V. (2007). Unusually severe expression of craniofacial features in Aarskog–Scott syndrome due to a novel truncating mutation of the FGD1 gene. American Journal of Medical Genetics. Part A, 143(1), 58–63. https://doi.org/10.1002/ajmg.a.31562
Pasteris, N. G., Cadle, A., Logie, L. J., Porteous, M. E., Schwartz, C. E., Stevenson, R. E., Glover, T. W., Wilroy, S., & Gorski, J. L. (1994). Isolation and characterization of the faciogenital dysplasia (Aarskog–Scott syndrome) gene: A putative Rho/Rac guanine nucleotide exchange factor. Cell, 79(4), 669–678. https://doi.org/10.1016/0092-8674(94)90552-5
Pilozi-Edmonds, L., Maher, T. A., Basran, R. K., Milunsky, A., Al-Thihli, K., Braverman, N. E., & Alfares, A. (2011). Fraternal twins with Aarskog–Scott syndrome due to maternal germ line mosaicism. American Journal of Medical Genetics Part A, 155(8), 1987–1990. https://doi.org/10.1002/ajmg.a.34094
Ronce, N., Maystadt, I., Hubert, C., Vonwill, S., Devriendt, K., Moizard, M. P., & Raynaud, M. (2012). Aarskog–Scott syndrome: First report of a duplication in the FGD1 gene. Clinical Genetics, 82(1), 93–96. https://doi.org/10.1111/j.1399-0004.2011.01782.x
Schwartz, C. E., Gillessen-Kaesbach, G., May, M., Cappa, M., Gorski, J., Steinid, K., & Neri, G. (2000). Two novel mutations confirm FGD1 is responsible for the Aarskog syndrome. European Journal of Human Genetics, 8(11), 869–874. https://doi.org/10.1038/sj.ejhg.5200553
Teebi, A. S., Rucquoi, J. K., & Meyn, M. S. (1993). Aarskog syndrome: Report of a family with review and discussion of nosology. American Journal of Medical Genetics, 46(5), 501–509. https://doi.org/10.1002/ajmg.1320460508
Verhoeven, W. M., Egger, J. I., & Hoogeboom, A. J. (2012). X-linked Aarskog syndrome: Report on a novel FGD1 gene mutation. Executive
dysfunction as part of the behavioural phenotype. Genetic Counseling, 23(2), 157–167.

Whitehead, I. P., Abe, K., Gorski, J. L., & Der, C. J. (1998). CDC42 and FGD1 cause distinct signaling and transforming activities. Molecular and Cellular Biology, 18(8), 4689–4697. https://doi.org/10.1128/MCB.18.8.4689

Zanetti Drumond, V., Sousa Salgado, L., Sousa Salgado, C., Oliveira, V. A. L., de Assis, E. M., Campos Ribeiro, M., Valadão, A. F., & Orrico, A. (2021). The prevalence of clinical features in patients with Aarskog-Scott syndrome and assessment of genotype-phenotype correlation: A systematic review. Genetics Research, 2021, 6652957. https://doi.org/10.1155/2021/6652957

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Bayat, A., Krett, B., Duna, M., Torring, P. M., & Vissing, J. (2022). Novel truncating variants in FGD1 detected in two Danish families with Aarskog-Scott syndrome and myopathic features. American Journal of Medical Genetics Part A, 188A:2251–2257. https://doi.org/10.1002/ajmg.a.62753